1.Effect of secretory leukocyte protease inhibitor on growth regulation of dermal mesenchymal stem cells
Journal of Chongqing Medical University 1986;0(03):-
Objective:To investigate the expression of SLPI in dMSCs and the effect of SLPI on growth regulaton of dMSCs.Method :Isolated stem cells from the rat skin tissue.Two pieces of sterile polyvinyl alcohol sponges were inserted subcutaneously in the dorsum of the rat and collected the wound fluid 1day after injury.Isolated RNA of two groups:dMSCs before and after the stimulation by wound fluid;skin tissue before and after trauma.SLPI was detected to know how they changed in dMSCs and in the skin before and after the injure by using RT-PCR and Western blot method.[H3] Thymidine incorporation was used to evaluate the mitogenic influence of SLPI.Results:Most of the neonatal dMSCs were spindle-shaped cells and exhibited multilineage potential in vitro.It was shown in the result of RT-PCR and western blot that SLPI expressed in dMSCs and increased after the cells being stimulated by wound fluid.A concentration-dependent proliferation promotion were demonstrated in dMSCs incubated for 24h in the prsense of SLPI.Conclusions:SLPI can be detected in dMSCs and support the growth of dMSCs in serum-free medium in vitro.In view of the multiple functions of SLPI,we supposed that it acted as an important role when dMSCs participated in the reparing of cutaneous injury.
2.Meropenem for Treatment of Hospital Acquired Pneumonia: A Clinical Trial
Depeng JIANG ; Jing XIANG ; Jianqiong XIONG
Chinese Journal of Nosocomiology 2006;0(08):-
OBJECTIVE To evaluate the efficacy and safety of meropenem as first choice for hospital acquired pneumonia(HAP) treatment in intensive care units(ICU) in Southwest Hospital. METHODS The usage of meropenem for the patients with HAP in ICU was studied by a prospective,open,and non-comparative trial.Prior to the clinical trial,the preliminary experiment on etiologic investigation was done through bronchoalveolar lavage and blood cultures.In the trial,all patients were treated intravenously with meropenem at a dose of 1g every 8 hours and(3 to 7 days) were established as a treatment duration period. RESULTS After the meropenem therapy,35 patients(66%) showed either cure or improvement.Mortality was 11% at the end of therapy.Clinical complications were observed in 11 patients(21%),with none of them definitely related to the study drug. CONCLUSIONS Meropenem is effective and well-tolerated as monotherapy for most HAP patients in our ICU.The low mortality rate in this study might have been attributed to the first choice use of this drug.
3.Application of Hussman's preoperative risk assessment in predicting the intraoperative complications
Depeng XU ; Yanyan ZHANG ; Chao WANG ; Lei YANG ; Fuyan MA ; Chunyi LIU ; Xuecheng JIANG
The Journal of Clinical Anesthesiology 2017;33(6):546-549
Objective To explore relationship of the anesthetic risks and intraoperative complications.Methods Preoperative anesthetic risks were assessed with Hussman's method from May 2015 to May 2016 in 2 494 surgical patients, including 1 462 males and 1 032 females.Intraoperative data and complications were tracked and recorded.Results Three hundred and thirty-six intraoperative complications occurred, accounting for 13.47% of total patients.The cardiovascular complications were a major intraoperative complications, accounting for 80.7%.2 494 patients were graded respectively into risk grade 1 with 1 540 (61.75%), grade 2 with 660 (26.46%), grade 3 with 202 (8.10%), grade 4 with 80 (3.21%) and grade 5 with 12 (0.48%).The incidence of complications were 112 (7.28%), 82 (12.42%), 82 (40.59%), 50 (62.50%) and 10 (83.33%) respectively.The sensitivity of prediction was 33.33%, 24.40%, 24.40%, 14.88% and 2.78%;the specificity 33.76%, 73.26%, 94.44%, 98.61% and 99.91%;and the accuracy 33.76%, 66.64%, 85.01%, 87.33% and 86.85%, respectively, in patients with risk grade 1, 2, 3, 4 and 5.Conclusion Hussman's method of anesthetic risks well predicts the intraoperative complications.
4.Efficacy of high-dose dexamethasone plus low-dose rituximab as a second-line treatment in 65 patients with primary immune thrombocytopenia.
Zhiling YAN ; Zhenyu LI ; Huanxin ZHANG ; Chong CHEN ; Depeng LI ; Weiwei XING ; Hujun LI ; Wei CHEN ; Hai CHENG ; Jiang CAO ; Kailin XU
Chinese Journal of Hematology 2015;36(3):206-209
OBJECTIVETo observe the efficacy of high-dose dexamethasone in combination with low-dose rituximab as a second-line treatment for patients with immune thrombocytopenia (ITP).
METHODS65 patients with ITP, previously by conventional dose of glucocorticoids, received high-dose dexamethasone in combination with low-dose rituximab (dexamethasone 40 mg/d for 4 days, rituximab 100 mg, d 7, 14, 21, 28 intravenous infusion). Treatment response, regulatory T cells (Treg), cytokines levels and treatment-related adverse effects were observed.
RESULTSTotal response rate 1 month after treatment was achieved in 81.5% (53/65) of patients, and complete response at 3,6 and 12 months was 72.3% (47/65), 66.2%(43/65), 63.1%(41/65). The higher efficiency and complete response rate was achieved in preexisting glucocorticoid-dependent patients. For patients with complete response, Treg cells continued to show a high level state [(3.01 ± 0.95)% vs (1.69 ± 0.35)%, P=0.032], cytokines of BAFF [(648.03 ± 79.63) ng/L vs (972.35 ± 93.64) ng/L, P=0.001], IL-2 [(2.84 ± 0.32) ng/L vs (4.18 ± 0.46) ng/L, P=0.012], sCD40L[(4.55 ± 0.66) ng/L vs (7.73 ± 1.04) ng/L, P=0.006] significantly lower than that before treatment. The level of IL-10 was increased, but without significance compared with that before treatment (P=0.136). All patients completed the protocol with no serious adverse reactions.
CONCLUSIONThe data show high-dose dexamethasone in combination with low-dose rituximab still has a satisfactory outcomes for patients previously with conventional dose of glucocorticoid.
Antibodies, Monoclonal, Murine-Derived ; Cytokines ; Dexamethasone ; Drug Combinations ; Glucocorticoids ; Humans ; Purpura, Thrombocytopenic, Idiopathic ; Rituximab ; T-Lymphocytes, Regulatory